《HOLRBT与TURBT治疗非肌层浸润性膀胱癌的研究进展》一、引言非肌层浸润性膀胱癌（NMIBC）是泌尿系统常见的恶性肿瘤之一，其治疗方式的选择对于患者的预后和生活质量具有重要影响。
近年来，随着医疗技术的不断进步，HOLRBT（Holmium Laser Resection of Bladder Tumor）和TURBT（Transurethral Resection of Bladder Tumor）作为非肌层浸润性膀胱癌的主要治疗手段，其研究进展备受关注。
本文将就HOLRBT与TURBT治疗非肌层浸润性膀胱癌的研究进展进行详细阐述。
二、HOLRBT治疗非肌层浸润性膀胱癌的研究进展HOLRBT是一种新型的膀胱肿瘤治疗方法，其利用高功率激光技术对膀胱肿瘤进行切除。
相较于传统的TURBT，HOLRBT 具有手术时间短、术中出血量少、术后恢复快等优点。
近年来，HOLRBT在非肌层浸润性膀胱癌的治疗中得到了广泛应用，并取得了良好的临床效果。
研究显示，HOLRBT对于小至中等大小的膀胱肿瘤具有较好的治疗效果，其切除效果与TURBT相当，且术后并发症发生率较低。
此外，HOLRBT还可以有效减少术后肿瘤复发的风险，提高患者的生存率。
在手术过程中，HOLRBT还可以通过激光能量对肿瘤组织进行消融，进一步减少肿瘤细胞的扩散和转移。
三、TURBT治疗非肌层浸润性膀胱癌的研究进展TURBT作为非肌层浸润性膀胱癌的经典治疗方法，其疗效和安全性已经得到了广泛认可。
近年来，随着手术技术的不断改进和辅助治疗手段的增多，TURBT在治疗非肌层浸润性膀胱癌方面的研究也取得了新的进展。
在手术技术方面，微创TURBT逐渐成为主流，通过使用微创器械和内镜技术，可以减少手术创伤和术后恢复时间。
此外，术中联合使用化疗药物可以提高TURBT的疗效，减少肿瘤复发的风险。
在辅助治疗方面，免疫治疗和靶向治疗等新型治疗方法也逐渐应用于TURBT术后，为患者提供了更多的治疗选择。
索利那新治疗非肌层浸润性膀胱癌患者膀胱灌注后膀胱刺激征的疗效评价摘要目的：探究索利那新对非肌层浸润性膀胱癌（NMIBC）患者膀胱灌注治疗后膀胱刺激症状的疗效及安全性。
方法：选取2021年3月1日至2022年6月30日江汉大学附属医院泌尿外科收治的60例NMIBC患者。
所有患者均因初发膀胱癌行经尿道膀胱肿瘤电切术（TURBT），术后病理结果证实为NMIBC，术后均用表柔比星行膀胱灌注化疗，所有患者随机分为观察组和对照组各30例。
TURBT后第一日开始服用药物，观察组口服索利那新5mg/d，连续5天；对照组口服安慰剂5mg/d，连续5天。
在膀胱灌注治疗第 1、2、5 天分别记录两组患者膀胱过度活动症症状评分(OABSS)和生活质量评分(QOL)。
结果：两组患者年龄、性别、肿瘤大小、肿瘤分期、手术时间等基本资料之间相比，结果显示差异无统计学意义（p＜0.05）。
与对照组相比，灌注治疗第1天、第2天观察组患者OABSS明显降低，差异具有统计学意义（p＜0.05）；灌注治疗第5天，两组患者OABSS 比较差异无统计学意义（p＞0.05）。
灌注治疗第1天、第2天、第5天，观察组患者QOL均低于对照组，差异具有统计学意义（p＜0.05）。
观察组有两例患者出现口干的不良反应。
结论：索利那新能改善NMIBC患者膀胱灌注后膀胱刺激症状，提高患者生活质量。
关键词非肌层浸润性膀胱癌；膀胱灌注；索利那新；膀胱刺激征Evaluation of the efficacy of solifenacin in bladder irritation symptoms after bladder perfusionin patients with non-muscle invasive bladder cancerWang Yiwei，Zhu Tao(School of Medicine, Jianghan University, Wuhan 430056, Hubei, China)【Abstract】Objective To explore the efficacy and safety of solifenacin for bladder irritation symptoms after bladder perfusion in patients with non-muscle invasive bladder cancer（NMIBC）. Methods 60 NMIBC patients admitted to the Department of Urology of Jianghan University Affiliated Hospital from March 1, 2021 to June 30, 2022 were selected. All patients underwent transurethral resection of the bladder tumor (TURBT) for primary bladder cancer, postoperative pathological findings confirmed NMIBC, postoperative bladder perfusion chemotherapy with epirubicin, All the patients were randomly pidedinto 30 cases each of the observation and control groups. Take medicine on the first day after TURBT, Observation group received oral solifenacin 5 mg/d for 5 consecutive days; the control group received oral placebo for 5 mg/d for 5 consecutive days. Overactive bladder symptom score (OABSS) and quality of life score (QOL) of the both patient groups were recorded on days 1,2 and 5 of bladder perfusion therapy. Results：Compared with the basic data, such as age, sex, tumor size, tumor stage and time of surgery, the results showed no statistically significant difference（p＜0.05）. Compared with the control group, OABSS was significantly decreased in the observation group on days 1 and 2 of perfusion treatment, difference was statistically significant（p＜0.05）; On day 5 of perfusion treatment, the OABSS varied significantly（p＞0.05）.On days 1,2 and 5 days of perfusion treatment, the QOL was lower than that of the control group, difference was statistically significant（p＜0.05）.Two patients in the observation group had adverse reactions of the dry mouth. Conclusion：Solfenacin can improve the symptoms of bladder stimulation after bladder perfusion and improve the quality of life of patients with NMIBC.【Key words】non-muscle invasive bladder cancer; bladder perfusion; solifenacin; bladder irritation symptoms膀胱癌（bladder cancer, BC）是威胁人类健康的常见恶性肿瘤之一，居所有恶性肿瘤新发病例第13位，也是泌尿系统最常见的肿瘤之一[1]。
吉西他滨膀胱灌注治疗复发性非肌层浸润性膀胱癌的临床研究金刚;张奇夫;杨新平;田玉新【期刊名称】《中国医学前沿杂志（电子版）》【年(卷),期】2014(000)010【摘要】目的：评价吉西他滨膀胱灌注化疗治疗常规膀胱灌注化疗失败的非肌层浸润性膀胱癌（NMIBC）的有效性及耐受性。
方法采用随机数表法将48例持续常规膀胱灌注化疗1年内出现肿瘤复发的NMIBC患者均分为A、B、C三组，每组各16例。
A组患者给予1000 mg吉西他滨灌洗， B组患者给予2000 mg吉西他滨灌洗，C组患者则继续采用原化疗方案灌洗。
分析三组患者2年肿瘤复发率、复发进展率及不良反应发生情况。
结果 A、B组患者2年肿瘤无复发生存率（68.75%，75.00%）明显高于C组（18.75%），通过log-rank test检验，A、B组与C组比较差异具有显著性（P＜0.05），但A组与B组差异无显著性（χ2＝0.246，P＝0.620）。
三组患者2年肿瘤复发进展率分别为25.00%、18.75%、25.00％，组间比较差异无显著性（χ2＝0.253，P＝0.881）。
三组患者不良反应发生率分别为31.25%、25.00%、37.50%，组间比较差异无显著性（χ2＝0.582，P＝0.748）。
不良反应主要表现为尿频、尿急、尿痛等，经对症治疗后缓解，未发生严重的血液学不良反应。
结论吉西他滨膀胱灌注化疗对常规膀胱灌注化疗后复发的NMIBC疗效显著，降低高危NMIBC复发率，但对膀胱肿瘤进展无明显预防作用，且不同剂量间的疗效未见明显差异。
%ObjectiveTo evaluate the efficacy and tolerability of intravesical gemcitabine after first-line in travesical chemotherapy failure in the treatment of non-muscle-invasive bladdercancer (NMIBC).Method 48 patients with NMIBC, who had tumorrecurrence within one year of ifrst-line intravesical chemotherapy, were assigned to 3 groups (16 cases in each group). Group A received intravesical gemcitabine in a dose of 1000 mg, group B received 2000 mg gemcitabine, and group C received original intravesical chemotherapy. Analyzed three groups of patients 2 years tunor recurrence rates, incidence of recurrence rate and adverse reaction.ResultGroup A and B of 2 years tumor free survival (68.75%, 75.00%) were higher than that in group C (18.75%), by log-rank-test tested between group A, B and group C were statistically signiifcant differences (P<0.05), but group A and group B had no signiifcant difference (χ2=0.246,P=0.620). Three groups of 2 year recurrence progression rates were 25.00%, 18.75%, 25.00%, and no signiifcant difference between three groups (χ2=0.253, P=0.881). Three groups of adverse reaction rate were 31.25%, 25.00%, 37.50%, there was no statistical difference between groups (χ2=0.582, P=0.748). Adverse reactions among three groups weres urinary frequency, urgency, dysuria, hematuria, relieved by symptomatic treatment, no serious haematological adverse reactions.ConclusionIntravesical chemotherapy with gemcitabine is well tolerated and effective for patients with high risk NMIBC, however, which treatment dose not reduce tumor progress, and the effect of different dose have no signiifcant difference.【总页数】3页(P129-131)【作者】金刚;张奇夫;杨新平;田玉新【作者单位】吉林省肿瘤医院泌尿外科，长春130041;吉林省肿瘤医院泌尿外科，长春130041;吉林省肿瘤医院泌尿外科，长春130041;吉林省肿瘤医院泌尿外科，长春130041【正文语种】中文【相关文献】1.吉西他滨膀胱灌注治疗复发性非肌层浸润性膀胱癌的疗效分析 [J], 白云金;杨玉帛;韩平;魏强;唐寅;王晓明;蒲春晓;李金洪2.吉西他滨膀胱灌注治疗非肌层浸润性膀胱癌的临床研究 [J], 王琳;孙启慧;赵先英3.手术后吉西他滨和表柔比星序贯膀胱灌注治疗非肌层浸润性膀胱癌患者的效果[J], 张卓4.经尿道等离子电切术结合吉西他滨膀胱灌注治疗非肌层浸润性膀胱癌的临床有效性 [J], 崔传威;于艳;倪亮亮;杨海生;赵玉海5.吉西他滨膀胱灌注治疗非肌层浸润性膀胱癌的疗效及血清VEGF的影响 [J], 王龙;王健;佟发春;翟成喜;刘昀瓒;邓仁强;王彬因版权原因，仅展示原文概要，查看原文内容请购买。
